Format
Sort by
Items per page

Send to

Choose Destination

Best matches for iloprost AND pulmonary hypertension:

Search results

Items: 1 to 20 of 596

1.

Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study.

Colaci M, Lumetti F, Giuggioli D, Guiducci S, Bellando-Randone S, Fiori G, Matucci-Cerinic M, Ferri C.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):179-183. Epub 2017 Sep 18.

PMID:
28980901
2.

Pulmonary hypertension: Clinical parameters of a difficult case in pregnancy.

Calhoun BC.

Linacre Q. 2017 Aug;84(3):243-247. doi: 10.1080/00243639.2016.1173812. Epub 2017 Aug 22.

PMID:
28912617
3.

The Second-Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model.

Dwyer-Nield L, Hickey GA, Friedman M, Choo K, McArthur DG, Tennis MA, New ML, Geraci M, Keith RL.

Cancer Prev Res (Phila). 2017 Aug 29. doi: 10.1158/1940-6207.CAPR-17-0050. [Epub ahead of print]

PMID:
28851689
4.

A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.

Theodoraki K, Thanopoulos A, Rellia P, Leontiadis E, Zarkalis D, Perreas K, Antoniou T.

Heart Vessels. 2017 Jul 17. doi: 10.1007/s00380-017-1023-2. [Epub ahead of print]

PMID:
28717881
5.

Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension.

Li XY, Zheng Y, Long Y, Zhang X, Zhang L, Tian D, Zhou D, Lv QZ.

Clin Exp Pharmacol Physiol. 2017 Sep;44(9):914-923. doi: 10.1111/1440-1681.12796.

6.

Prostacyclins have no direct inotropic effect on isolated atrial strips from the normal and pressure-overloaded human right heart.

Holmboe S, Andersen A, Jensen RV, Kimose HH, Ilkjær LB, Shen L, Clapp LH, Nielsen-Kudsk JE.

Pulm Circ. 2017 Apr-Jun;7(2):339-347. doi: 10.1177/2045893217691532. Epub 2017 May 30.

7.

The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension.

Gessler T, Ghofrani HA, Held M, Klose H, Leuchte H, Olschewski H, Rosenkranz S, Fels L, Li N, Ren D, Kaiser A, Schultze-Mosgau MH, Müllinger B, Rohde B, Seeger W.

Pulm Circ. 2017 Apr-Jun;7(2):505-513. doi: 10.1177/2045893217706691. Epub 2017 May 12.

8.

Inhaled Pulmonary Vasodilator Therapy for Management of Right Ventricular Dysfunction after Left Ventricular Assist Device Placement and Cardiac Transplantation.

Sabato LA, Salerno DM, Moretz JD, Jennings DL.

Pharmacotherapy. 2017 Aug;37(8):944-955. doi: 10.1002/phar.1959. Epub 2017 Jul 14. Review.

PMID:
28543813
9.

Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.

Honorato Pérez J.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):753-762. doi: 10.1080/17512433.2017.1322900. Epub 2017 May 19. Review.

PMID:
28524738
10.

Iloprost Instillation in Two Neonates with Pulmonary Hypertension.

Unal S, Aktas S, Aksu M, Hirfanoglu IM, Atalay Y, Turkyilmaz C.

J Coll Physicians Surg Pak. 2017 Apr;27(4):257-259.

PMID:
28492159
11.

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.

Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.

J Pharmacol Exp Ther. 2017 Jul;362(1):186-199. doi: 10.1124/jpet.116.239665. Epub 2017 May 5.

PMID:
28476928
12.

The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.

Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P.

Expert Rev Respir Med. 2017 Jun;11(6):491-503. doi: 10.1080/17476348.2017.1317599. Epub 2017 Apr 24.

PMID:
28399721
13.

[Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].

Moiseeva OM, Rudakova AV.

Ter Arkh. 2017;89(3):72-77. doi: 10.17116/terarkh201789372-77. Russian.

PMID:
28378734
14.

[Hemodynamic Predictors of Clinical Deterioration in Patients With Pulmonary Arterial Hypertension Associated With Systemic Scleroderma].

Nikolaeva EV, Kurmukov IA, Yudkina NN, Glukhova SI, Volkov AV.

Kardiologiia. 2016 Oct;56(10):46-54. Russian.

PMID:
28290895
15.

Treatment of Chronic Thromboembolic Pulmonary Hypertension: The Role of Medical Therapy and Balloon Pulmonary Angioplasty.

Fernandes TM, Poch DS, Auger WR.

Methodist Debakey Cardiovasc J. 2016 Oct-Dec;12(4):205-212. doi: 10.14797/mdcj-12-4-205. Review.

16.

Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension.

Xu QX, Yang YH, Geng J, Zhai ZG, Gong JN, Li JF, Tang X, Wang C.

Chin Med J (Engl). 2017 Feb 20;130(4):382-391. doi: 10.4103/0366-6999.199829.

17.
18.

Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.

Han X, Zhang Y, Dong L, Fang L, Chai Y, Niu M, Yu Y, Liu L, Yang X, Qu S, Li S.

Respir Care. 2017 Apr;62(4):489-496. doi: 10.4187/respcare.05280. Epub 2017 Jan 24.

PMID:
28119496
19.

A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.

Fuchikami C, Murakami K, Tajima K, Homan J, Kosugi K, Kuramoto K, Oka M, Kuwano K.

Eur J Pharmacol. 2017 Jan 15;795:75-83. doi: 10.1016/j.ejphar.2016.11.057. Epub 2016 Dec 3.

PMID:
27919660
20.

Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.

Trombetta AC, Pizzorni C, Ruaro B, Paolino S, Sulli A, Smith V, Cutolo M.

J Rheumatol. 2016 Nov;43(11):2033-2041. Epub 2016 Oct 1.

Supplemental Content

Loading ...
Support Center